The monoamine model of depression has long formed the basis of drug development but
fails to explain treatment resistance or associations with stress or inflammation. Recent …

The versatility of glutamate as the brain's foremost excitatory neurotransmitter and modulator
of neurotransmission and function is considered common knowledge. Years of research …

Glutamate, a major excitatory neurotransmitter, plays important roles in synaptic plasticity,
such as long-term potentiation (LTP) and new synapse formation. Growing evidence …

Half a century after the first formulation of the monoamine hypothesis, compelling evidence
implies that long-term changes in an array of brain areas and circuits mediating complex …

Increasing data indicate that inflammation and alterations in glutamate neurotransmission
are two novel pathways to pathophysiology in mood disorders. The primary goal of this …

Two of the dominant theories regarding the development of depression and its response (or
lack thereof) to conventional antidepressant therapies involve excessive activation of …

There has been increasing interest in the role of glutamate in mood disorders, especially
given the profound effect of the glutamate receptor antagonist ketamine in improving …

Recent compelling evidence has suggested that the glutamate system is a primary mediator
of psychiatric pathology and also a target for rapid-acting antidepressants. Clinical research …

Accumulating evidence indicates that dysfunction in amino acid neurotransmission
contributes to the pathophysiology of depression. Consequently, the modulation of amino …

Excessive glutamate release has been linked to stress and many neurodegenerative
diseases. Evidence indicates abnormalities of glutamatergic neurotransmission or …